menu

Medical Program: Special Considerations in NSCLC: Treating PD-L1 High Patients

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Special Considerations in NSCLC: Treating PD-L1 High Patients

close
Special Considerations in NSCLC: Treating PD-L1 High Patients
Restart
Resume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida. 

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 7/11/20